Answers are grounded in this paper and cite their sources.
For decades, apolipoprotein (Apo)E has reigned as the undisputed leader of lipoprotein genetics [1]. For many years, the impact of ApoE polymorphisms on plasma low-density lipoprotein (LDL)-cholesterol concentrations has been demonstrated in a reproducible fashion [2,3]. Moreover, several population studies have also shown how this genetic variability could be used to predict disease risk above and beyond traditional risk factors [4]. The interest in ApoE polymorphisms increased further when this major regulator of lipid metabolism was first implicated in the risk for neurological disorders and then for all types of chronic disorders (i.e., cancer and osteoporosis). Moreover, consistent with the knowledge that, for the population at large, the individual cardiovascular disease (CVD) risk is neither 100% genetic or environmental, ApoE has repeatedly shown significant gene–environment interactions modulating its association with plasma lipid parameters as well as CVD risk [5]. Thus, the ApoE gene has been considered as the paradigm of genetic associations and interactions within the lipid and CVD fields.
No takes yet. Share an insight, caveat, or question.
José M. Ordovás (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: